{
  "docId": "019de076-8fd6-709e-8689-4f849e880c13",
  "docSlug": "045f5237a1062f1479093c113a295dbd",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 29 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 29,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8fd6-709e-8689-4f849e880c13/22",
  "deckHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13",
  "deckJsonHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13.json",
  "deckAnchorHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Safety and Tolerability: Generally well tolerated, mild/transient TEAEs, no serious AEs, no liver enzyme or visual issues.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a24d53e-8b04-4c2b-ac87-29b287abd6bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Efficacy: Statistically significant improvement in MWT scores, dose-dependent effect, Phase 2 dose range selected (4, 6, 8 mg).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c41e7035-0213-4aab-9b8a-45420522990e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 2680: Results From Full NT1 (n=10) Cohort Support Advancement to Phase 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0347596e-e354-4748-9e01-cea53f9a3d75",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 20,
      "beatId": "684f34f1-a86c-4f27-a384-190507ef00a2",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "The deck presents Alkermes' solution with ALKS 2680 and its development pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 16,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "58d89332-74ab-4a79-b132-80fa9e87fcdc",
      "evidence": "The deck presents a problem statement on orexin dysfunction and Alkermes' solution.",
      "position": 0,
      "objective": "What if Alkermes doesn't address orexin dysfunction?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 23,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "6855712d-cfcc-4ba8-90cd-9f606eb2639a",
      "evidence": "The deck presents results from ALKS 2680 clinical trials.",
      "position": 1,
      "objective": "What are the results of ALKS 2680?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}